![]() | Up a level |
Wiviott, SD, Raz, I, Bonaca, MP, Mosenzon, O, Kato, ET, Cahn, A, Silverman, MG, Zelniker, TA, Kuder, JF, Murphy, SA et al (show 10 more authors)
(2019)
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
NEW ENGLAND JOURNAL OF MEDICINE, 380 (4).
pp. 347-357.
Zelniker, TA, Raz, I, Mosenzon, O, Dwyer, JP, Heerspink, HJL, Cahn, A, Im, K, Bhatt, DL, Leiter, LA, McGuire, DK et al (show 5 more authors)
(2019)
Effect of dapagliflozin on cardiovascular outcomes in patients with type 2 diabetes according to baseline renal function and albuminuria status: Insights from DECLARE-TIMI 58.
.